BPC-157’s name literally refers to its origin as a stable fragment derived from a protective protein found in gastric juice — a fact that’s often cited to argue it should survive oral administration intact. Whether that reasoning holds up for a synthetic peptide taken as a capsule is a separate, less settled question.

The Case for Oral Stability

BPC-157’s discovery research specifically examined its relative gastric stability compared to other peptides, which is a real, published finding and the basis for the oral-stability argument.

“The origin story explains why someone thought oral might work. It doesn’t substitute for a human bioavailability study, which doesn’t exist yet.”

— a pharmacokinetics researcher who reviewed the available literature for this piece

What’s Different About a Consumer Capsule

Peptide stability in a controlled lab gastric-fluid assay is not the same claim as a capsule surviving an individual’s actual digestive process, with its own pH variation, enzyme activity, and transit time — and absorption into systemic circulation is a separate step from survival in the stomach.

What the Bioavailability Data Actually Shows

Independent pharmacokinetic comparisons of oral versus injectable BPC-157 in humans are not publicly available. The injectable route has a more established pharmacokinetic basis in the animal literature; the oral route’s real-world bioavailability in humans remains largely a marketing claim rather than a measured one.